Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
STTK Stock Chart & Stats
$3.90
>-$0.01(-0.39%)
At close: 4:00 PM EST
$3.90
>-$0.01(-0.39%)
Day’s Range― - ―
52-Week Range$0.69 - $4.89
Previous CloseN/A
Volume43.14K
Average Volume (3M)550.09K
Market Cap
$243.63M
Enterprise Value$143.64M
Total Cash (Recent Filing)$42.55M
Total Debt (Recent Filing)$1.76M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Mar 17, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding63,279,842
10 Day Avg. Volume553,172
30 Day Avg. Volume550,087
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.77
Price to Sales (P/S)10.74
P/FCF Ratio-1.01
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue143.64
Enterprise Value/Gross Profit-166.05
Enterprise Value/Ebitda-2.72
Forecast
1Y Price Target
$8.33Price Target Upside113.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical MilestoneAnalyst highlights an upcoming Phase I readout scheduled for the second quarter of 2026 on safety, receptor occupancy, immunogenicity and pharmacokinetics as a potential de‑risking event that could reshape program valuation.
Immunogenicity ProfileAnalyst expects SL-325's cell-bound design to lower the likelihood of anti‑drug antibody formation, which may preserve treatment effect and enable combination therapy strategies.
Mechanism DifferentiationAnalyst notes SL-325's targeting of the DR3 receptor could provide stronger and more durable reduction of intestinal inflammation compared with TL1A blockade, offering a clear mechanism-based differentiation in inflammatory disease treatment.
Bears Say
Commercial CompetitionAnalyst notes commercial risks from a crowded therapeutic landscape and uncertain market adoption, which could limit market share and revenue even if clinical results are positive.
Financing RiskAnalyst warns that the company's early-stage status creates financing risk that may necessitate future capital raises, with possible dilution if resources are insufficient for later-stage development.
Regulatory UncertaintyAnalyst flags regulatory uncertainty and potential clinical setbacks that could require additional trials or data, increasing the risk of approval delays or added development costs.
Shattuck Labs News
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $0.69 and its highest was $4.89 in the past 12 months.
What is Shattuck Labs’s market cap?
Shattuck Labs’s market cap is $243.63M.
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Mar 17, 2026 which is in 40 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on Nov 06, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.149 by $0.009.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -0.14.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 63,279,842 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.149. Following the earnings report the stock price went up 1.02%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shattuck Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.15%
12-Months-Change
Fundamentals
Return on Equity
-57.84%
Trailing 12-Months
Asset Growth
-49.95%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
STTK Stock 12 Month Forecast
Average Price Target
$8.33
▲(113.59% Upside)
Technical Analysis
PolyPid
―
Coeptis Therapeutics Holdings
―
―
Xilio Therapeutics
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
16.42% Insiders
3.54% Mutual Funds
0.21% Other Institutional Investors
76.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---